Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Prevail Therapeutics
With
Eli Lilly and Company
Age
0–2
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Bi-allelic GBA1 mutations consistent with a diagnosis of GD2 confirmed by the central laboratory.
Clinical diagnosis of GD2
Parent/legal guardian is capable of providing signed informed consent; including compliance with the requirements and restrictions listed in the informed consent form (ICF) in this protocol.
Patient has a parent/legal guardian able to participate in the study as a source of information on the patient's health status and cognitive and functional abilities (including providing input into the rating scales).
You may not be if
Significant CNS disease other than GD2 that may be a cause for the patient's symptoms or interfere with study objectives.
Achieved independent gait.
Severe peripheral symptoms of GD which, in the opinion of the Investigator, would pose an unacceptable risk to the patient or interfere with the patient's ability to comply with study procedures or interfere with the conduct of the study.
Concomitant disease, condition, or treatment which, in the opinion of the Investigator, would pose an unacceptable risk to the patient or interfere with the patient's ability to comply with study procedures or interfere with the conduct of the study.
Use of any substrate reduction therapy (SRT) for GD treatment.
Use of prohibited medications, herbals, or over-the-counter agents as listed in the protocol.
Any type of prior gene or cell therapy.
Use of systemic immunosuppressant or corticosteroid therapy other than protocol-specified immunosuppression.
Participation in another investigational drug or device study within the past 3 months.
Brain MRI (magnetic resonance imaging) and MRA (magnetic resonance angiography) showing clinically significant abnormality deemed a contraindication to intracisternal injection.
Clinically significant laboratory test result abnormalities assessed at screening.
Contraindications or intolerance to radiographic visualization methods (e.g. MRI, MRA, CT), and intolerance to contrast agents used for MRI or CT scans.
Contraindications to general anesthesia or sedation.
Clareo Health | Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)
